TGA reviews new COVID-19 vaccines for JN.1 variant

abc.net.au

Australia's Therapeutic Goods Administration (TGA) is reviewing two new COVID-19 vaccines targeting the JN.1 variant, submitted by Pfizer and Moderna. The updated vaccines aim to enhance protection against emerging sub-variants. The TGA typically evaluates applications within 45 working days. Current vaccines provide 50-60% protection against symptomatic disease and 80-90% against severe illness. Approval could lead to availability by November or December 2024.


With a significance score of 6.4, this news ranks in the top 0.1% of today's 25041 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


TGA reviews new COVID-19 vaccines for JN.1 variant | News Minimalist